Wall Street analysts expect that EXACT Sciences Co. (NASDAQ:EXAS) will report $127.32 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for EXACT Sciences’ earnings, with the lowest sales estimate coming in at $125.90 million and the highest estimate coming in at $129.14 million. EXACT Sciences reported sales of $87.41 million during the same quarter last year, which indicates a positive year-over-year growth rate of 45.7%. The business is scheduled to issue its next quarterly earnings report on Thursday, February 28th.
On average, analysts expect that EXACT Sciences will report full year sales of $438.79 million for the current fiscal year, with estimates ranging from $437.40 million to $440.62 million. For the next financial year, analysts forecast that the company will post sales of $705.21 million, with estimates ranging from $701.40 million to $709.90 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for EXACT Sciences.
EXACT Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Tuesday, October 30th. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. EXACT Sciences had a negative net margin of 35.83% and a negative return on equity of 20.18%. The firm had revenue of $118.29 million for the quarter, compared to analysts’ expectations of $109.33 million. During the same quarter in the previous year, the company earned ($0.23) earnings per share. The company’s revenue for the quarter was up 63.0% compared to the same quarter last year.
In related news, insider D Scott Coward sold 2,190 shares of the business’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $79.51, for a total transaction of $174,126.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Michael S. Wyzga sold 2,468 shares of the business’s stock in a transaction dated Tuesday, August 28th. The shares were sold at an average price of $74.85, for a total transaction of $184,729.80. Following the transaction, the director now owns 9,112 shares in the company, valued at approximately $682,033.20. The disclosure for this sale can be found here. Insiders have sold 389,436 shares of company stock worth $27,603,229 in the last quarter. 3.20% of the stock is owned by corporate insiders.
Large investors have recently bought and sold shares of the stock. First Republic Investment Management Inc. bought a new stake in EXACT Sciences during the third quarter worth about $204,000. Fulton Bank N.A. bought a new stake in EXACT Sciences during the third quarter worth about $208,000. Crossmark Global Holdings Inc. bought a new stake in EXACT Sciences during the third quarter worth about $220,000. Mogy Joel R Investment Counsel Inc. bought a new stake in EXACT Sciences during the third quarter worth about $221,000. Finally, GWM Advisors LLC bought a new stake in EXACT Sciences during the third quarter worth about $223,000. 89.70% of the stock is currently owned by institutional investors and hedge funds.
EXAS stock opened at $67.06 on Friday. EXACT Sciences has a 12-month low of $37.36 and a 12-month high of $81.22. The stock has a market capitalization of $8.18 billion, a price-to-earnings ratio of -67.74 and a beta of 1.21. The company has a debt-to-equity ratio of 0.94, a quick ratio of 11.72 and a current ratio of 12.08.
EXACT Sciences Company Profile
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
See Also: Bull Market
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.